

Candioli Innovation

actea®

The new frontier
in dermatology
for dogs and cats

actea®

DERMO

with



Exclusive
patented*
formula



*world patent n. WO 2016/046108

ACTEA® and LAS® are registered trademarks by Candioli Pharma

www.candioli-vet.it

Candioli
PHARMA

Dermatitis in dogs and cats



Dermatitis in dogs and cats represent one of the most common causes for veterinary visits²¹. Among these are localised forms of erythematous, which are associated with bacterial super-infection and/or yeasts and are especially frequent^{14,20,33}.

MAIN CAUSES^{8,9,22,26,27,28}

Atopy
Food allergy
Ectoparasitic diseases

PREDISPOSING FACTORS^{10,12,25,33}

Epidermal barrier malfunction
Seborrhoea
Breed predisposition




Photo by Dr. A. Vercelli

COMPLICATING MICRO-ORGANISMS^{1,2,4,6,14}

Bacteria: *Staphylococcus pseudintermedius* and *aureus*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *E. coli*
Yeasts: *Malassezia pachydermatis*


MAIN SYMPTOMS^{8,9,15,22,26}

Itching
Oedema and redness
Alopecia


Essential bibliography

1. Beck KM, Waisglass SE, Dick H, Weese JS. Prevalence of methicillin-resistant *Staphylococcus pseudintermedius* (MRSP) from skin and carriage sites of dogs after treatment of their methicillin-resistant or methicillin-sensitive staphylococcal pyoderma. *Vet Derm* 2012;23:369
2. Bond R, Loeffler A. What's happened to *Staphylococcus intermedius*? Taxonomic revision and emergence of multi-drug resistance. *J Small Anim Pract* 2012;53:147-154
3. Bonina FP, Gimigliaro D, Melandri F, Pressi G. Protective effect of topical formulations based on glycerophosphoinositol choline salt. *Dermatologia Ambulatoriale* 2006;4
4. Cafarchia C, Gatto S, Capelli G, Otranto D. Frequenza e distribuzione quantitativa dei lieviti del genere *Malassezia* in cani sani e in cani con dermatite e otite. *Veterinaria* 2005;19(1):15-20
5. Carlotti DN, Gatto H. L'arte della shampoo terapia nel cane e nel gatto: strategie di trattamento e prevenzione in dermatologia. *Veterinaria* 2005;19(1):29-39
6. Colombo S. I lieviti del genere *Malassezia* nelle malattie dermatologiche del cane e del gatto. *Veterinaria* 2007;21(4):25-31
7. Corda D, Falasca M. Glycerophosphoinositols as potential markers of Ras-induced transformation and novel second messengers. *Anticancer Research* 1996;16:1341-1350
8. DeBoer DJ. Advances in canine atopic dermatitis. *WSAVA World Congress Proceedings* 2010
9. DeBoer DJ. Atopic dermatitis: management plans. *NAVC Conference Proceedings* 2011
10. DeBoer DJ. Barrier function and atopic dermatitis. *NAVC Conference Proceedings* 2011
11. Di Biase AM, et al. Effect of bovine lactoferricin on enteropathogenic *Yersinia* adhesion and invasion in HEp-2 cells. *Journal of Medical Microbiology* 2004;53:407-412
12. Falconi Klein E, Carrera C, Richelmi P. Evaluation of protective and dermo-balancing of a product for normalizing scalp psoriasis, by clinical trial use of polarized light camera and TEWL. *Biobasic Europe (Milan) University of Pavia, May 2003 (Report n. 0201L07-05F)*
13. Gifford JL, et al. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. *Cell Mol Life Sci* 2005;62(22):2588-98
14. Gotthelf L. Topical treatment of *Malassezia*. *NAVC Conference Proceedings* 2011
15. Hillier A, et al. Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animals Infectious Disease). *Vet Derm* 2014;25:163-e43

Staphylococcus, skin infections and antimicrobial resistance



Staphylococci are gram-positive facultative anaerobic bacteria, which are commonly found on the skin and mucous membrane of mammals and birds¹. With regard to *Staphylococcus pseudintermedius*, particularly high colonising rates were noted in dogs and cats and, as an opportunistic pathogen, is **the most commonly found bacterium in cases of skin infection in these species**^{1,2,15,20}.



As was the case with humans, also in veterinary medicine, staphylococci, and in particular *Staphylococcus pseudintermedius* (recently reclassification of *Staphylococcus intermedius*), have **recently developed a growing resistance to the most commonly used antibiotics** (beta-lactams, quinolones, cephalosporins)^{1,2,15,20}.



This, in part, came about by an **excessive use of systemic antibiotic therapies**^{15,19}, thus suggesting the adoption of more prudent use of these molecules (FECAVA Working Group on Hygiene and the Use of Antimicrobials in Veterinary Practice, 2013), as well as **encouraging the use of topical products containing antibacterial substances that induce lower risks of antimicrobial resistance**^{1,2,15,19,20}. Amongst these are some **peptides** that exert antimicrobial activity¹⁹, such as those that can alter the permeability of the cell membrane of the bacterium^{11,13,16}.

16. Hoeck KS, et al. Antibacterial activity of bovine lactoferrin-derived peptides. *Antimicrobial Agents and Chemotherapy* 1997;41(1):54-59
17. Istituto Profilattico e Farmaceutico Candioli & C S.p.A. Antibacterial spectrum of Lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. Data on file 2014-patent pending
18. Korkina LG. Dermasyr sebum regulating activity. Russian State Medical University, Moscow, Russia Data on file 2005
19. Leonard BC, et al. Antimicrobial peptides: agents of border protection for companion animals. *Vet Derm* 2012;23(3):177-e36
20. Lloyd DH. Optimizing topical therapy in the treatment of skin disease. *WSAVA World Congress Proceedings* 2010
21. Lund E. Epidemiologia della dermatite atopica canina. *Veterinary Focus* 2011;21(3):32-33
22. Marsella R. Dermatite atopica del cane: quadri clinici. *Quaderni di Dermatologia* 2004;9(1):13-14
23. Motolese A, Simonelli M. Effect of glycerophosphoinositol salt of choline 1% cream on mild-to-moderate inflammatory and allergic dermatitis. *Dermatological Experiences* 2008;10:135-40

24. Nielsen TD, et al. Survey of the UK veterinary profession: common species and condition nominated by veterinarians in practice. *Vet Rec* 2014;174(13):324
25. Noli C. I disturbi di cheratinizzazione primari e secondari. *Quaderni di Dermatologia* 2005;10(2):15-19
26. Olivry T, et al. Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials. *Vet Derm* 2010;21:4-22
27. Olivry T, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International task Force on Canine Atopic dermatitis. *Vet Derm* 2010;21:233-248
28. Olivry T, Sousa CA. The ACVD task force on canine atopic dermatitis (XIX): general principles of therapy. *Vet Immunol Immunopathol* 2001;81:311-316
29. Oo TZ, et al. Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection. *J Antimicrob Chemother* 2010 doi:10.1093/jac/dkq106
30. Pastore S, et al. Plant polyphenols regulate chemokine expression and tissue repair in human keratinocytes through interaction with cytoplasmic and nuclear components of epidermal growth factor receptor system. *Antioxidants and Redox Signaling* 2012;16(4):314-328



LAS® is a patented* mixture based on:

- 🌀 **Lactoferricin** – *hydrolysed lactoferrin (peptide)*
- 🌀 **GPI** – *glycerophosphoinositol lysine** – semisynthetic derivative of sunflower lecithin*
- 🌀 **Verbascoside** (Dermasyr™)*** – *derived from plant stem cells (Syringa vulgaris)*

LAS® components have the following properties upon topical application:

- ✓ Reduce **inflammation** and **itching**^{3,7,12,23,30,36,38,40,41}
- ✓ Moderate **skin dehydration** (TEWL - Trans Epidermal Water Loss)¹²
- ✓ Counteract **seborrhoea** and the subsequent development of **bacteria** and **yeasts**^{18,40}
- ✓ Exert **antibacterial**^{11,13,17,29,34,37} and immunostimulatory **activity**^{13,17,37}

LAS® mixtures boast of good bioavailability.

Actea® Dermo formula is enriched in soy lecithin, which contains 85% essential fatty acids (alpha-linolenic acid, linoleic acid) and has the properties to develop micellar structures, which **guarantee maximum absorption of LAS® actives.**

BEFORE



AFTER 15 DAYS OF USE



photo by Dr. A. Vercelli

*world patent n. WD 2016/046108 (registered trademark of Candioli Pharma)

** patent no. EP1332149-1

***Dermasyr™ is a registered trademark of Croda International Plc.

31. Pastore S, Korkina LG, Dal Toso R. Anti-inflammatory properties of naturally occurring biotechnologically produced phenylpropanoid glycosides. *Laboratory of tissue engineering and skin pathophysiology, Rome, Italy. 2009 data on file*

32. Pazzaglia M, Tosti A. Efficacy evaluation of a treatment with a glycerophosphoinositol choline lenitive lotion by scalp dermoscopy. *Department of Specialistic and Experimental Clinical Medicine-Unit of Dermatological Clinic, Alma Mater Studiorum University of Bologna, Jan 2007*

33. Power H, Prelaud P. Il ruolo della razza nelle malattie cutanee del cane. *Veterinary Focus 2011;21(3):10-17*

34. Sanchez-Gomez S, et al. Structural featurig governing the activity of lactoferricin-derived peptides that act in synergy with antibiotics against *Pseudomonas aeruginosa* in vitro and in vivo. *Antimicrobial Agents and Chemotherapy 2011;55(1):218-228*

35. Shestakov A, et al. Lactoferricin but not lactoferrin inhibit herpes simplex virus type 2 infection in mice. *Antiviral Res 2012;93(3):340-5*

36. Yahagi S, Izutsu Y, Okano Y, Pressi G, Dal Toso R, Masaki H. Glycerophosphoinositol is a novel modulator of cytosolic phospholipase A2 (cPLA2): its anti-inflammatory effects and a possible mechanism. *25th IFSCC Congress, Barcelona, 6-9 October 2008*

37. Wakabayashi H, et al. Lactoferricin derived from milk protein lactoferrin. *Curr Pharm Des 2003;9(16):1277-87*

38. In vitro evaluation of the irritation and anti-inflammatory potential of a topical cosmeceutic active. *Data on file 2003*

39. Occlusive patch-test results. Centro di Cosmetologia, Università di Ferrara. *Data on file 2015*

40. Patch-test with GPI lysine in healthy voluntary subjects. *Data on file 2009*

41. Photo-patching test with GPI choline in healthy voluntary subjects. *Data on file 2005*

42. Verbascoside Anti-Malassezia furfur activity. *Data on file 2010*

ACTEA® DERMO

Product features

What features must a good topical dermatological product have?

- ✓ **Easy** to apply and **well-tolerated**
- ✓ Effective in reducing **desquamation** and **skin dehydration**
- ✓ Active on **bacteria** (gram + and gram -) and **Malassezia**
- ✓ Able to **control inflammation and erythema**



The new solution


actea®
DERMO

thanks to its
innovative formula




Results of the occlusive patch test³⁹

ACTEA® Dermo was assessed as **NON-IRRITATING**



Number of responses of irritation (erythematous and/or oedematous) detected 15 minutes and 24 hours after removing the patch. The erythematous reactions were divided into three groups based on the erythema: slight, visible or moderate/serious.



Average index of irritation (total score). The dotted line indicates the limit beyond which the tested product causes slight irritation.



actea®

DERMO

The new frontier in dermatology

- Check the **desquamation** and **skin dehydration**
- Ideal as an **adjunct** to control **inflammation** and **itching**
- Reduces **bacterial** and **Malassezia overgrowth**
- Good **tolerability** without the risk of antimicrobial resistance



Product sheet

INDICATIONS

Lotion for dermatological use in cats and dogs indicated as an adjunct in treating skin conditions characterised by itching, redness, changes in hydrolipidic film and bacterial and fungal flora, also associated with excessive production of sebum and unpleasant odour. Thanks to its protective, soothing and sanitising properties, **Actea® Dermo** can even be used to prevent skin infections of various origins in predisposed subjects.

Actea® Dermo is generally recommended in all situations where the physiological conditions of the skin need to be restored.

COMPOSITION

Aqua (water), Propylene glycol, Sorbitol, Lactoferricin, Glycerophosphoinositol Lysine, Syringa vulgaris extract, Maltodextrin, Tocopherol, Lecithin, Arginine, Triclosan, Ricinus communis (castor) seed oil, Magnesium Aluminum silicate, Glycine hydrochloride, Ppg-26-buteth-26, Peg-40 hydrogenated castor oil, Carbomer, Benzyl alcohol, Ethylhexylglycerin, Phenoxyethanol.

HOW TO USE

Apply a suitable amount of product, according to the area of the skin surface to be treated, **twice a day**. Gently rub to assure the product is adequately spread over the surface of the skin and suitably penetrates the hydrolipidic film. **Repeat** the operation for **10-20 consecutive days**, until normal skin conditions are restored.



CANDIOLI S.r.l. u.s.
Strada Comunale di None, 1 - 10092 Beinasco (TO) - Italia
Tel. +39.011.34.90.232 - Fax +39.011.34.90.526 - www.candioli.it - email: info@candioli.it

Candioli
PHARMA